Specific Activity of Recombinant Modified Human Glucagon-Like Peptide 1

Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease

(2018) Jingjing Tai et al.   BRAIN RESEARCH

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program

(2016) Johan Jendle et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Weight management in obesity - past and present

(2016) D. Haslam   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems

(2016) Dongdong Zhang et al.   JOURNAL OF CONTROLLED RELEASE

Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants

(2016)   LANCET

The Modified Heparin-Binding l-Asparaginase of Wolinella succinogenes

(2016) E. P. Sannikova et al.   MOLECULAR BIOTECHNOLOGY

Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review

(2016) Amrita Ostawal et al.   Diabetes Therapy

Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review

(2016) Amrita Ostawal et al.   Diabetes Therapy

Split Ssp DnaB mini-intein-mediated production of recombinant human glucagon-like peptide-1/7-36

(2015) Aiqin Jiang et al.   BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

(2015) Jesper Lau et al.   JOURNAL OF MEDICINAL CHEMISTRY

The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease

(2014) Christian Hölscher   Alzheimers & Dementia

Long-Acting GLP-1 Analogue in V-Shaped Conformation by Terminal Polylysine Modifications

(2014) Xue Yang et al.   MOLECULAR PHARMACEUTICS

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

(2014) Brian Finan et al.   NATURE MEDICINE

Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreaticβ-cells GLP-1促进胰岛素分泌和胰岛β细胞增殖的机制

(2014) Xiaosong Ma et al.   Journal of Diabetes

Cell-Penetrating Peptide-Mediated Therapeutic Molecule Delivery into the Central Nervous System

(2013) Li-Li Zou et al.   Current Neuropharmacology

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)

(2013) J. Rosenstock et al.   DIABETES CARE

An Evidence-Based and Practical Approach to Using Bydureon  in Patients With Type 2 Diabetes

(2013) N. A. Painter et al.   Journal of the American Board of Family Medicine

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

(2013) B. Finan et al.   Science Translational Medicine

Recombinant production of mGLP-1 by coupling of refolding and intein-mediated self-cleavage (CRIS)

(2012) Mingming Gao et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Intein-Mediated Expression and Purification of an Analog of Glucagon-like Peptide-1 in Escherichia coli

(2010) Chen Ma et al.   PROTEIN AND PEPTIDE LETTERS

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

(2009) J. Rosenstock et al.   DIABETES CARE

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

(2009) Jonathan W Day et al.   Nature Chemical Biology